MS and Demyelinating Disorders

A recent analysis highlights the increasing use of Octave's MSDA test in managing multiple sclerosis, showcasing its impact on treatment decisions and disease monitoring.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 8, 2025.

Gabrielle Macaron, MD, assistant professor of neuroscience at Université de Montréal, discussed the nuanced clinical decision-making involved in initiating a DMT for patients newly diagnosed with MS.

At CMSC 2025, Cassandra Moore, MPH, CPH, associate vice president of strategy and innovation at the National MS Society, discussed the impact of health and wellness coaching in patients with multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Findings from a new study from Mayo Clinic may offer clinicians a straightforward metric lesion resolution to aid them in distinguishing MOGAD from MS in routine clinical practice.

Helius reported promising results for its Portable Neuromodulation Stimulator, enhancing gait and balance in poststroke patients, with FDA submission planned.

Navigating insurance hurdles for multiple sclerosis treatments poses significant risks, as seen in a patient's devastating relapse after denied care.

Here's some of what is coming soon to NeurologyLive® this week.

A recent research letter emphasized that meningitis could be a possible early manifestation of MOG antibody–associated disease, according to results previously published in an international study.

A recent survey revealed significant variability in treatment decisions for pediatric MOGAD, highlighting gaps in knowledge and the potential need for improved clinical guidelines.

Here's some of what is coming soon to NeurologyLive® this week.

A recent study reveals a decline in multiple sclerosis progression rates, highlighting the impact of improved treatments and the need for ongoing innovation in care.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 4, 2025.

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could potentially reshape patient care.

Here's some of what is coming soon to NeurologyLive® this week.

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 20, 2025.

Helius Medical Technologies expands access to its PoNS device for patients with MS as Aetna joins major payers in coverage, enhancing treatment options.

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.

The ExTINGUISH trial investigates inebilizumab's efficacy for NMDAR encephalitis, aiming to enhance treatment options for diverse patient populations.

Recent MR analysis uncovers protein associations with neuromyelitis optica spectrum disorder, suggesting new treatment pathways and drug targets for improved management.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 13, 2025.

Sam Hooshmand, DO, assistant professor of neurology at the Medical College of Wisconsin, discussed the complexities of defining, diagnosing, and managing advanced MS.

Neurology News Network. for the week ending June 7, 2025. [WATCH TIME: 4 minutes]

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]